SCM
AARD

Sterling Capital Management’s Aardvark Therapeutics AARD Stock Holding History

Sterling Capital Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-233
Closed -$878 – 3443
2026
Q1 		$878 Sell
233
-112
-32% -$1.16K ﹤0.01% 3105
2025
Q4 		$4.53K Buy
345
+163
+90% +$2.03K ﹤0.01% 2921
2025
Q3 		$2.42K Buy
182
+107
+143% +$1.21K ﹤0.01% 2949
2025
Q2 		$1.01K Buy
+75
New +$773 ﹤0.01% 3059

Other funds holding AARD

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Sterling Capital Management's AARD Position: Q2 2026 in Review

Sterling Capital Management sold out of Aardvark Therapeutics (AARD) in Q2 2026, closing a stake of 233 shares — an estimated $878 sold.

Sterling Capital Management first reported a position in AARD in Q2 2025 and held it in 4 quarters. The position peaked at $4.53K in Q4 2025. 13 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Sterling Capital Management reported no remaining Aardvark Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sterling Capital Management sold 233 Aardvark Therapeutics shares in Q2 2026, an estimated $878.
  • Sterling Capital Management first reported a position in Aardvark Therapeutics in Q2 2025 and held it in 4 quarters.
  • Sterling Capital Management's Aardvark Therapeutics position peaked at $4.53K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.